Pretreatment with memantine prevents Alzheimer-like alterations induced by intrahippocampal okadaic acid administration in rats

Current Alzheimer Research

Volumn 9, Issue 10, 2012, Pages 1182-1190

  Zimmer, Eduardo Rigon ^a   Kalinine, Eduardo ^a   Haas, Clarissa Branco ^a   Torrez, Vitor Rocco ^a   Souza, Diogo Onofre ^a   Muller, Alexandre Pastoris ^a   Portela, Luis Valmor ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Alzheimer's disease; Cdk5; Glutamate; Learning and memory; Memantine; Okadaic acid; Tau

Indexed keywords

CYCLIN DEPENDENT KINASE 5; GLUTAMIC ACID; MEMANTINE; OKADAIC ACID; PROTEIN P25; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DRUG EFFICACY; HIPPOCAMPUS; LOCOMOTION; MALE; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SPATIAL MEMORY;

ALZHEIMER DISEASE; ANIMALS; CARCINOGENS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLIN-DEPENDENT KINASE 5; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; EXCITATORY AMINO ACID ANTAGONISTS; EXPLORATORY BEHAVIOR; GLUTAMIC ACID; HIPPOCAMPUS; LOCOMOTION; MALE; MAZE LEARNING; MEMANTINE; OKADAIC ACID; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; STATISTICS AS TOPIC; TAU PROTEINS;

EID: 84874916126     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720512804142877     Document Type: Article

References (66)

1. Ho YS, KF So, RC Chang. Anti-aging herbal medicine--how and why can they be used in aging-associated neurodegenerative diseases? Ageing Res Rev 9(3): 354-62 (2010).
2. Katzman R. Alzheimer's disease. N Engl J Med 314(15): 964-73 (1986).
3. Delbeuck X, M Van der Linden, F Collette. Alzheimer's disease as a disconnection syndrome? Neuropsychol Rev 13(2): 79-92 (2003).
4. Citron, M. Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov 9(5): 387-98 (2010).
5. McGeer PL, McGeer EG. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging 28(5): 639-47 (2007).
6. Nicolakakis NE Hamel. Neurovascular function in Alzheimer's disease patients and experimental models. J Cereb Blood Flow Metab (2011).
7. Sonkusare SK, Kaul CL, Ramarao P. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope. Pharmacol Res 51(1): 1-17 (2005).
8. Hollmann M, Heinemann S. Cloned glutamate receptors. Annu Rev Neurosci 17: 31-108 (1994).
9. Headley PM, Grillner S. Excitatory amino acids and synaptic transmission: the evidence for a physiological function. Trends Pharmacol Sci 11(5): 205-11 (1990).
10. Danbolt NC. Glutamate uptake. Prog Neurobiol 65(1): 1-105 (2001).
11. Maragakis NJ, Rothstein JD. Glutamate transporters: animal models to neurologic disease. Neurobiol Dis 15(3): 461-73 (2004).
12. Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate receptor ion channels. Pharmacol Rev 51(1): 7-61 (1999).
13. Filali M, Lalonde R, Rivest S. Subchronic memantine administration on spatial learning, exploratory activity, and nestbuilding in an APP/PS1 mouse model of Alzheimer's disease. Neuropharmacology 60(6): 930-6 (2011).
14. Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH, et al. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402(6762): 615-22 (1999).
15. Crews L, Masliah E. Molecular mechanisms of neurodegeneration in Alzheimer's disease. Hum Mol Genet 19(R1): R12-20 (2010).
16. Zhang S, Edelmann L, Liu J, Crandall JE, Morabito MA. Cdk5 regulates the phosphorylation of tyrosine 1472 NR2B and the surface expression of NMDA receptors. J Neurosci 28(2): 415-24 (2008).
17. Peskind ER, Potkin SG, Pomara N, Ott BR, Graham SM, Olin JT, et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 14(8): 704-15 (2006).
18. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291(3): 317-24 (2004).
19. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Möbius HJ, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348(14): 1333-41 (2003).
20. Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 14(2): 135-46 (1999).
21. van Marum RJ. Update on the use of memantine in Alzheimer's disease. Neuropsychiatr Dis Treat 5: 237-47 (2009).
22. Johnson JW, Kotermanski SE. Mechanism of action of memantine. Curr Opin Pharmacol 6(1): 61-7 (2006).
23. Babu CS, Ramanathan M. Pre-ischemic treatment with memantine reversed the neurochemical and behavioural parameters but not energy metabolites in middle cerebral artery occluded rats. Pharmacol Biochem Behav 92(3): 424-32 (2009).
24. Kamat PK, Tota S, Saxena G, Shukla R, Nath C. Okadaic acid (ICV) induced memory impairment in rats: a suitable experimental model to test anti-dementia activity. Brain Res 1309: 66-74 (2010).
25. Arendt T, Holzer M, Fruth R, Bruckner MK, Gartner U. Paired helical filament-like phosphorylation of tau, deposition of beta/A4-amyloid and memory impairment in rat induced by chronic inhibition of phosphatase 1 and 2A. Neuroscience 69(3): 691-8 (1995).
26. Arendt T, Holzer M, Bruckner MK, Janke C, Gartner U. The use of okadaic acid in vivo and the induction of molecular changes typical for Alzheimer's disease. Neuroscience 85(4): 1337-40 (1998).
27. Arias C, Montiel T, Pena F, Ferrera P, Tapia R. Okadaic acid induces epileptic seizures and hyperphosphorylation of the NR2B subunit of the NMDA receptor in rat hippocampus in vivo. Exp Neurol 177(1): 284-91 (2002).
28. Bennecib M, Gong CX, Grundke-Iqbal I, Iqbal K. Role of protein phosphatase-2A and -1 in the regulation of GSK-3, cdk5 and cdc2 and the phosphorylation of tau in rat forebrain. FEBS Lett 485(1): 87-93 (2000).
29. Reddy PH. Abnormal tau, mitochondrial dysfunction, impaired axonal transport of mitochondria, and synaptic deprivation in Alzheimer's disease. Brain Res 1415: 136-48 (2011).
30. Zhang B, Carroll J, Trojanowski JQ, Yao Y, Iba M, Potuzak JS, et al. The microtubule-stabilizing agent, epothilone d, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J Neurosci 32(11): 3601-11 (2012).
31. Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53(3): 337-51 (2007).
32. Leasure JL, Decker L. Social isolation prevents exercise-induced proliferation of hippocampal progenitor cells in female rats. Hippocampus 19(10): 907-12 (2009).
33. Abdel-Aal RA, Assi AA, Kostandy BB. Memantine prevents aluminum-induced cognitive deficit in rats. Behav Brain Res 225(1): 31-8 (2011).
34. Paxinos GC Watson, The rat brain in stereotaxic coordinates. 2nd ed. 1986, Sydney; Orlando: Academic Press. xxvi, 237 p. of plates.
35. Arias C, Becerra-Garcia F, Arrieta I, Tapia R. The protein phosphatase inhibitor okadaic acid induces heat shock protein expression and neurodegeneration in rat hippocampus in vivo. Exp Neurol 153(2): 242-54 (1998).
36. He J, Yamada K, Zou LB, Nabeshima T. Spatial memory deficit and neurodegeneration induced by the direct injection of okadaic acid into the hippocampus in rats. J Neural Transm 108(12): 1435-43 (2001).
37. He J, Yang Y, Xu H, Zhang X, Li XM. Olanzapine attenuates the okadaic acid-induced spatial memory impairment and hippocampal cell death in rats. Neuropsychopharmacology 30(8): 1511-20 (2005).
38. Prut L, Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol 463(1-3): 3-33 (2003).
39. Muller AP, Tort AH, Gnoatto J, Moreira JD, Vinadé ER, Perry ML, et al. Metabolic and behavioral effects of chronic olanzapine treatment and cafeteria diet in rats. Behav Pharmacol 21(7): 668-75 (2010).
40. Peterson GL. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem 83(2): 346-56 (1977).
41. Abramoff MD, Magalhaes PJ, Ram SJ. Processing with ImageJ. Biophotonics International 11(7): 36-42 (2004).
42. Iqbal K, Grundke-Iqbal I. Developing pharmacological therapies for Alzheimer disease. Cell Mol Life Sci 64(17): 2234-44 (2007).
43. Zhang Z, Simpkins JW. An okadaic acid-induced model of tauopathy and cognitive deficiency. Brain Res 1359: 233-46 (2010).
44. Sun L, Liu SY, Zhou XW, Wang XC, Liu R, Wang Q, et al. Inhibition of protein phosphatase 2A-and protein phosphatase 1-induced tau hyperphosphorylation and impairment of spatial memory retention in rats. Neuroscience 118(4): 1175-82 (2003).
45. Genoux D, Haditsch U, Knobloch M, Michalon A, Storm D, Mansuy IM. Protein phosphatase 1 is a molecular constraint on learning and memory. Nature 418(6901): 970-5 (2002).
46. Shenolikar S. Protein serine/threonine phosphatases--new avenues for cell regulation. Annu Rev Cell Biol 10: 55-86 (1994).
47. Hu NW, Ondrejcak T, Rowan MJ. Glutamate receptors in preclinical research on Alzheimer's disease: Update on recent advances. Pharmacol Biochem Behav (2011).
48. Chohan MO, Khatoon S, Iqbal IG, Iqbal K. Involvement of I2PP2A in the abnormal hyperphosphorylation of tau and its reversal by Memantine. FEBS Lett 580(16): 3973-9 (2006).
49. Kaiser E, Schoenknecht P, Kassner S, Hildebrandt W, Kinscherf R, Schroeder J, et al. Cerebrospinal fluid concentrations of functionally important amino acids and metabolic compounds in patients with mild cognitive impairment and Alzheimer's disease. Neurodegener Dis 7(4): 251-9 (2010).
50. Lu CW, Lin TY, Wang SJ. Memantine depresses glutamate release through inhibition of voltage-dependent Ca2+ entry and protein kinase C in rat cerebral cortex nerve terminals: an NMDA receptor-independent mechanism. Neurochem Int 57(2): 168-76 (2010).
51. Gong CX, Liu F, Grundke-Iqbal I, Iqbal K. Post-translational modifications of tau protein in Alzheimer's disease. J Neural Transm 112(6): 813-38 (2005).
52. Liu F, Liang Z, Shi J, Yin D, El-Akkad E, Grundke-Iqbal I, et al. PKA modulates GSK-3beta-and cdk5-catalyzed phosphorylation of tau in site-and kinase-specific manners. FEBS Lett 580(26): 6269-74 (2006).
53. Tsai LH, Delalle I, Caviness VS, Jr., Chae T, Harlow E. p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature 371(6496): 419-23 (1994).
54. Lew J, Huang QQ, Qi Z, Winkfein RJ, Aebersold R, Hunt T, et al. A brain-specific activator of cyclin-dependent kinase 5. Nature 371(6496): 423-6 (1994).
55. Wang J, Liu S, Fu Y, Wang JH, Lu Y. Cdk5 activation induces hippocampal CA1 cell death by directly phosphorylating NMDA receptors. Nat Neurosci 6(10): 1039-47 (2003).
56. Dhavan R, Tsai LH. A decade of CDK5. Nat Rev Mol Cell Biol 2(10): 749-59 (2001).
57. Barnett DG, Bibb JA. The role of Cdk5 in cognition and neuropsychiatric and neurological pathology. Brain Res Bull 85(1-2): 9-13 (2011).
58. Stomrud E, Hansson O, Zetterberg H, Blennow K, Minthon L, Londos E. Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. Arch Neurol 67(2): 217-23 (2010).
59. Jimenez-Jimenez FJ, Molina JA, Gomez P, Vargas C, de Bustos F, Benito-León J, et al. Neurotransmitter amino acids in cerebrospinal fluid of patients with Alzheimer's disease. J Neural Transm 105(2-3): 269-77 (1998).
60. Smith CC, Bowen DM, Francis PT, Snowden JS, Neary D. Putative amino acid transmitters in lumbar cerebrospinal fluid of patients with histologically verified Alzheimer's dementia. J Neurol Neurosurg Psychiatry 48(5): 469-71 (1985).
61. Tan ZS, Beiser AS, Vasan RS, Roubenoff R, Dinarello CA, Harris TB, et al. Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology 68(22): 1902-8 (2007).
62. Reitz CR Mayeux. Use of genetic variation as biomarkers for Alzheimer's disease. Ann NY Acad Sci 1180: 75-96 (2009).
63. van Exel E, P Eikelenboom, Comijs H, Frölich M, Smit JH, Stek ML, et al. Vascular factors and markers of inflammation in offspring with a parental history of late-onset Alzheimer disease. Arch Gen Psychiatry 66(11): 1263-70 (2009).
64. Shoji M. Biomarkers of the dementia. Int J Alzheimers Dis 2011: 564321 (2011).
65. van Harten AC, Kester MI, Visser PJ, Blankenstein MA, Pijnenburg YA, van der Flier WM, et al. Tau and p-tau as CSF biomarkers in dementia: a meta-analysis. Clin Chem Lab Med 49(3): 353-66 (2011).
66. Vialatte FB, Dauwels J, Maurice M, Musha T, Cichocki A. Improving the specificity of EEG for diagnosing Alzheimer's disease. Int J Alzheimers Dis 2011: 259069 (2011).